Related Experiment Videos

Photoaffinity labeling of melanocyte-stimulating hormone receptors

A N Eberle¹, P N de Graan, T Scimonelli

¹Department of Research (ZLF), University Hospital, Basel, Switzerland.

Pharmacology & Therapeutics

|January 1, 1989

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2019

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2015

Molecular mechanisms involved in interleukin 1-beta (IL-1β)-induced memory impairment. Modulation by alpha-melanocyte-stimulating hormone (α-MSH).

Brain, behavior, and immunity·2013

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

British journal of cancer·2011

See all related articles